PT  - JOURNAL ARTICLE
AU  - Alexander, Lori
ED  - Armitage, Jane
TI  - HPS2-THRIVE Results
DP  - 2012 Nov 01
TA  - MD Conference Express
PG  - 27--28
VI  - 12
IP  - 13
4099  - http://mdc.sagepub.com/content/12/13/27.short
4100  - http://mdc.sagepub.com/content/12/13/27.full
AB  - Approximately two thirds of patients can tolerate extended-release niacin when combined with laropiprant, according to a prespecified interim safety and tolerability analysis of the Heart Protection Study 2: Treatment of HDL to Reduce the Incidence of Vascular Events [HPS2-THRIVE; NCT00461630] study. The addition of niacin/laropiprant to statin therapy offers a dual goal of decreasing low-density lipoprotein-cholesterol and increasing high-density lipoprotein-cholesterol.